Pay in 4 interest-free payments of $7.08 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
References & Sources SURPASS-2 Trial (N Engl J Med) SURMOUNT-1 Trial (N Engl J Med) SELECT Trial Semaglutide CV Outcomes (N Engl J Med) SUMMIT Trial Tirzepatide HFpEF (N Engl J Med) Eli Lilly SURPASS-2 Results (Press Release) Eli Lilly SURMOUNT-1 Results (Press Release) ADA SURPASS Data Presentation SUMMIT Trial ACC Summary SELECT Trial ACC Summary Disclaimer: This information is intended for general knowledge and informational purposes only and does not constitute medical advice
Include supporting documentation from your provider, relevant clinical studies, and any evidence that alternative treatments have been tried and failed
Even though obesity and other metabolic disorders are known to be higher in IBD patients, medications to treat obesity in this population are underutilized
The broader comparison across GLP-1 compounds consistently places retatrutide at the top of efficacy rankings, though with correspondingly higher side effect rates
(2024) 63:e202412585
You can seamlessly pair it with our comprehensive IV hydration treatments or explore our specialized wellness and detox services to create a personalized routine that truly delivers results you can feel
